Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific share transactions rather than a financial performance report.
Material Changes
The filing reports a specific increase in the notional allocation of GSK American Depositary Shares (ADSs) on April 10, 2015. This change resulted from the revaluation of the cash element of a notional investment held within the GSK 401K plan. The transaction occurred at a price of $48.23 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details the notification of a connected person's transaction.
Important Facts for Investors
- Transaction Date: April 10, 2015 (notified April 13, 2015).
- Connected Person: Dr K Slaoui (connected person of Dr M M Slaoui).
- Transaction Details: Increase of 4 ADSs.
- Price: $48.23 per ADS.
- Context: The transaction was a revaluation of a notional investment within the GSK 401K plan, not a direct market purchase.